Your Global Leader in Stem Cell Market Research
Stem cell research is a multi-billion dollar industry. The National Institutes of Health (NIH) allocated over $2Â billion per year for stem cell research in the U.S. Additionally, more than a million people around the world have been treated with stem cell therapies.
Growth of stem cell therapeutics has followed in sync with other many types of advanced therapies, including cellular therapies, gene therapies, exosomes, peptide therapeutics, and more. [Read more…]
Mesenchymal stem cells (MSCs) are a type of non-controversial, adult cell. When manipulated within a laboratory, then can be differentiated into the specialized cells found in skeletal tissues, such as cartilage cells (chondrocytes), bone cells (osteoblasts), and fat cells (adipocytes). In contrast, stem cells derived from embryos are capable of developing into all the different types of cells found in our body, which makes them more versatile than MSCs, but also more controversial. Induced pluripotent stem cells also exhibit greater pluripotency, but as modified cells, they come with a greater set of regulatory challenges. [Read more…]
For over a decade, platelet-rich plasma (PRP) dominated the minimally invasive hair restoration space. Its appeal lay in its simplicity: draw blood, spin it, inject the growth-factor-rich plasma back into the scalp. But while PRP sparked interest and delivered early signs of improvement, its limitations have become clearer over time. Many patients require repeated sessions, results vary widely, and follicular stimulation often plateaus. [Read more…]
The latest development in stem cell research – stem cell treatment for hair loss – shows great promise for stimulating new hair growth. It addresses the problem of thinning hair for both men and women.
When hair growth slows with age, many people feel despondent, depressed, less confident, or unhappy. The prospect of a continuing downhill slide makes the situation worse, which is why stem cell transplant for hair loss has become a large business in the last several decades. [Read more…]
Toulouse, January 22, 2026 — Cell-Easy, a CDMO specialized in the development and GMP manufacturing of Advanced Therapy Medicinal Products (ATMPs), announces a new clinical milestone achieved in close collaboration with Toulouse University Hospital (CHU Toulouse). The European Medicines Agency (EMA) has granted Clinical Trial Authorization (CTA) for AMUSE, a Phase 1/2 clinical trial evaluating the safety and efficacy of an allogeneic mesenchymal stromal cell (MSC) therapy in patients with systemic sclerosis presenting perioral fibrosis and functional impairment. [Read more…]
